SCA
CARM

SAC Capital Advisors’s Carisma Therapeutics CARM Stock Holding History

SAC Capital Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,211
Closed -$393K – 182
2014
Q1 		$393K Buy
+1,211
New +$363K ﹤0.01% 1293

Other funds holding CARM

TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAC Capital Advisors's CARM Position: Q2 2014 in Review

SAC Capital Advisors sold out of Carisma Therapeutics (CARM) in Q2 2014, closing a stake of 1,211 shares — an estimated $393K sold.

SAC Capital Advisors first reported a position in CARM in Q1 2014 and held it in 1 quarter. The position peaked at $393K in Q1 2014. 39 funds tracked by Wall St. Rank hold CARM as of Q2 2014.

  • SAC Capital Advisors reported no remaining Carisma Therapeutics position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 1,211 Carisma Therapeutics shares in Q2 2014, an estimated $393K.
  • SAC Capital Advisors first reported a position in Carisma Therapeutics in Q1 2014 and held it in 1 quarter.
  • SAC Capital Advisors's Carisma Therapeutics position peaked at $393K in Q1 2014.
  • 39 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.